Contents Guest Editors v Preface vi Introduction vii 1. Aetiopathogenesis of VAP revisited 1 H.D. Aya B and J. Rello 2. New approaches to the aetiological diagnosis of VAP 11 E. Bouza, A. Burillo and E. Cercenado 3. Biomarkers and VAP: results and perspectives 24 A. Torres and S. Ewig 4. VAP: approach to therapy 36 M.S. Niederman 5. New antibiotics for VAP 48 R.G. Wunderink 6. Aerosolised treatment for VAP 54 C-E. Luyt, A. Combes, A. Nieszkowska, J-L. Trouillet and J. Chastre 7. Impact of guidelines on HAP and VAP outcomes 66 A. Torres, M. Ferrer, R. Amaro and A. López-Giraldo 8. VAP prevention: pharmacological strategies 74 L.E. Morrow and M.H. Kollef 9. VAP prevention: non-pharmacological strategies 83 M. Valencia, G. Li Bassi and A. Torres 10. Animal models of VAP 98 D. Bruno, J. García-Morato and C.M. Luna 11. Viral VAP 113 C-E. Luyt, A. Combes, A. Nieszkowska, J-L. Trouillet and J. Chastre Number 53 September 2011